Devreese et al., 2011 - Google Patents
Anticardiolipin and anti-β2glycoprotein-I antibody cut-off values in the diagnosis of antiphospholipid syndrome: more than calculating the in-house 99th percentiles …Devreese et al., 2011
- Document ID
- 2565218509707336266
- Author
- Devreese K
- Van Hoecke F
- Publication year
- Publication venue
- Thrombosis research
External Links
Snippet
The laboratory criteria for the antiphospholipid syndrome (APS) include lupus anticoagulants (LAC), medium or high titer (N40 GPL or MPL, or N99th percentile) anticardiolipin antibodies (aCL) or anti-β2-glycoprotein I antibodies (aβ2GPI)(N99th …
- 208000003343 Antiphospholipid Syndrome 0 title abstract description 50
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/543—Immunoassay; Biospecific binding assay with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
- G06F17/30—Information retrieval; Database structures therefor; File system structures therefor
- G06F17/30861—Retrieval from the Internet, e.g. browsers
- G06F17/30864—Retrieval from the Internet, e.g. browsers by querying, e.g. search engines or meta-search engines, crawling techniques, push systems
- G06F17/30867—Retrieval from the Internet, e.g. browsers by querying, e.g. search engines or meta-search engines, crawling techniques, push systems with filtering and personalisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
- G06F17/30—Information retrieval; Database structures therefor; File system structures therefor
- G06F17/30286—Information retrieval; Database structures therefor; File system structures therefor in structured data stores
- G06F17/30386—Retrieval requests
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F9/00—Arrangements for programme control, e.g. control unit
- G06F9/06—Arrangements for programme control, e.g. control unit using stored programme, i.e. using internal store of processing equipment to receive and retain programme
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Devreese et al. | Anticardiolipin and anti-β2glycoprotein-I antibody cut-off values in the diagnosis of antiphospholipid syndrome: more than calculating the in-house 99th percentiles, even for new automated assays | |
Reber et al. | Proposals for the measurement of anti‐β2‐glycoprotein I antibodies. Standardization Group of the European Forum on Antiphospholipid Antibodies | |
Galli et al. | Invitation to a debate on the serological criteria that define the antiphospholipid syndrome | |
Chayoua et al. | Detection of anti-cardiolipin and anti-β2glycoprotein I antibodies differs between platforms without influence on association with clinical symptoms | |
Hovinga et al. | Measurement of ADAMTS‐13 activity in plasma by the FRETS‐VWF73 assay: comparison with other assay methods | |
Favaloro et al. | Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I—Anticardiolipin and anti-β2-glycoprotein I antibodies | |
Chayoua et al. | Is there an additional value in detecting anticardiolipin and anti-β2 glycoprotein I IgA antibodies in the antiphospholipid syndrome? | |
Montaruli et al. | Analytical and clinical comparison of different immunoassay systems for the detection of antiphospholipid antibodies | |
Alkema et al. | Autoantibody profiles in systemic sclerosis; a comparison of diagnostic tests | |
Chiang et al. | Screening for Wiskott-Aldrich syndrome by flow cytometry | |
Heikal et al. | Laboratory evaluation of anti-phospholipid syndrome: a preliminary prospective study of phosphatidylserine/prothrombin antibodies in an at-risk patient cohort | |
Echeverri et al. | Neutrophil CD64 expression, procalcitonin and presepsin are useful to differentiate infections from flares in SLE patients with SIRS | |
Kuwana et al. | Detection of circulating B cells secreting platelet-specific autoantibody is useful in the diagnosis of autoimmune thrombocytopenia | |
Wilke et al. | Diagnostic performance of point-of-care and central laboratory cardiac troponin assays in an emergency department | |
Favaloro et al. | Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required | |
Warkentin et al. | The use of well‐characterized sera for the assessment of new diagnostic enzyme‐immunoassays for the diagnosis of heparin‐induced thrombocytopenia | |
De Laat et al. | High‐avidity anti‐β2 glycoprotein I antibodies highly correlate with thrombosis in contrast to low‐avidity anti‐β2 glycoprotein I antibodies | |
Chung et al. | Clinical performance of anticardiolipin and antiβ2 glycoprotein I antibodies using a new automated chemiluminescent assay: superior thrombotic prediction of combined results measured by two different methods | |
Favaloro et al. | Variability in D-dimer reporting revisited | |
Chandler et al. | Lupus anticoagulant testing and anticoagulation do not mix: quantitation of discrepant results and potential approaches to reduce false positives | |
Jennings et al. | ISTH/SSC lupus anticoagulant testing guidelines: how far have these been adopted by laboratories? | |
Mohloanyane et al. | Recent HIV infections among newly diagnosed individuals living with HIV in rural Lesotho: Secondary data from the VIBRA cluster-randomized trial | |
Wong et al. | A consensus approach to the formulation of guidelines for laboratory testing and reporting of antiphospholipid antibody assays | |
Podolsky et al. | Choosing which in-hospital laboratory tests to target for intervention: a scoping review | |
Bor et al. | Revisiting the Phadia/EliA cut-off values for anticardiolipin and anti-β2-glycoprotein I antibodies: a systematic evaluation according to the guidelines |